Aviva Systems Biology

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

CH3 BioSystems LLC is a biotechnology company organized around intellectual property created through research in chemical biology and epigenetics. The products derived from this research enable our end users, Biologists, Chemists and Clinicians, to create new diagnostics and potential therapeutic treatments for human and animal diseases. We manufacturer molecular tools for faster, more efficient and safer methods to facilitate research discoveries.

Our patented CH3 antibody and other IP protected products provide scientists with a novel molecular toolkit to study protein methylation status in diseases like cancer, HIV and neurodevelopmental, autoimmune or cardiovascular disordered.

Our vision is to promote the growth of the field of protein methylation biology and to provide cutting edge clinically relevant pharmaceutical products of the 21st century.

Ocean Ridge Biosciences (ORB) is a South Florida-based contract research laboratory supporting pharmaceutical and biotechnology companies worldwide through innovative RNA and protein-based biomarker discovery services. ORB is headquartered in Deerfield Beach, Florida, near the geographic center of a rapidly developing South Florida Life Science Cluster and have served hundreds of academic and corporate researchers on basic research, preclinical and retrospective clinical trials.

ORB’s focuses on provision of bioassays and bioinformatics in five key areas: circulating small RNA, exosome characterization, microbiome RNA and DNA sequencing, multiplex immunoassays, and DNA polymorphism analysis. The company's vision is to utilize these information-rich assays for development of reliable multi-analyte companion diagnostic tests that are released to the market along with its client's new drugs. To that end, the company has recently partnered with Boca Biolistics Clinical Reference Laboratory on research use multiplex immunoassays intended for companion diagnostics discovery. The partnership has developed a validated 35-plex cytokine/ chemokine immunoassay that is performed in Boca Bio's CAP-accredited laboratory.

In addition to commercial services, ORB has continually participated in and supported innovative biomedical research at major institutions. The company’s services are mentioned in over 90 published scientific articles. ORB has engaged in research collaborations with several academic institutes focused on biomarker discovery in disease areas such as neurodegeneration, cardiovascular disease, and emphysema. Our partners on these projects have included research groups at Emory University, Roosevelt Hospital in New York, and the University of Miami. ORB is currently collaborating on development of biomarker sets relevant to PD-1 immunotherapies with potential research and diagnostic applications for advanced melanoma, hepatocellular carcinoma, and adenocarcinoma.

Amarex is a global, full-service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs (FDA Applications and meetings, Applications to International Health Authorities, GxP Compliance Audits), Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management, Medical Monitoring, Safety and Pharmacovigilance, and General Consulting. Amarex can take your product through the entire approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval application. Join our growing list of clients with approved products. Amarex provides high quality and cost efficient services.

Sign-up to receive invites to webinars, training courses and the latest cutting-edge information on clinical trials: https://go.pardot.com/l/129231/2020-07-27/39ng9k

Founded in 1989 by the University of Colorado, CPC has two divisions. CPC Clinical Research is an academically led, non-profit, clinical research organization offering Phase 1 - 4 clinical research leadership and management services to sponsors around the world. CPC Clinical Research specializes in innovative research including a proprietary program, the Endpoint Quality Intervention Program (EQuIP), that helps reduce variability in the collection of endpoint data, allowing more definitive answers to the study objectives.

CPC Community Health creates innovative and educational programs to implement established cardiovascular prevention national guidelines and best evidence in Colorado communities resulting in improved cardiovascular health.

CPC is affiliated with the University Of Colorado School Of Medicine, Denver Health and the National Jewish Health. CPC is also the clinical trials arm of the University of Colorado Charles C Gates Center for Regenerative Medicine & Stem Cell Biology whose goal is to understand the biology of stem cells in order to develop new therapies for debilitating diseases such as heart diseases and vascular diseases.

CPC CLINICAL RESEARCH MISSION

To unite academic leadership with operational expertise to optimize the quality of clinical research and improve health.

CPC COMMUNITY HEALTH MISSION

Our mission is to improve the health of all Coloradans by creating innovative community health programs that deliver evidence-based interventions.

Visit us at www.cpcmed.org and www.communityhealth.org